Matrix metalloproteinases 2 and 9 in central nervous system and their modification after vanadium inhalation

Journal of Applied Toxicology

Volumn 28, Issue 6, 2008, Pages 718-723

  Colin Barenque L ^a   Martinez Hernandez M G ^a   Baiza Gutman, L A ^a   Avila Costa, M R ^a   Ordonez Librado J L ^a   Bizarro Nevares, P ^b   Rodriguez Lara, V ^b   Pinon Zarate G ^b   Rojas Lemus, M ^b   Mussali Galante, P ^b   Fortoul, Teresa I ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Hippocampus; Metalloproteinase; MMP 2; MMP 9; Olfactory bulb; Prefrontal cortex; Striatum; Vanadium pentoxide

Indexed keywords

BRAIN ENZYME; GELATINASE A; GELATINASE B; VANADIUM PENTOXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITIC SPINE; ENZYME ACTIVATION; ENZYME MODIFICATION; HIPPOCAMPUS; MALE; MOUSE; NERVE CELL NECROSIS; NONHUMAN; OLFACTORY BULB; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXIC INHALATION; ZYMOGRAPHY;

ADMINISTRATION, INHALATION; ANIMALS; BRAIN; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM; DENSITOMETRY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; VANADIUM;

MUS;

EID: 49649104712     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1326     Document Type: Article

References (39)

1. Avila-Costa MR, Colín-Barenque L, Zepeda-Rodríguez A, Antuna SB, Saldivar O, Espejel-Maya G, Mussali-Galante P, Avila-Casado MC, Fortoul TI. 2005. Ependymal epithelium disruption after vanadium pentoxide inhalation. A mice experimental model. Neurosci. Lett. 381: 21-25.
2. 5) promote memory deterioration. Neurotoxicology 27: 1007-1012.
3. Avila-Costa MR, Montiel-Flores E, Colín-Barenque L, Ordoñez JL, Gutiérrez AL, Niño-Cabrera HG, Mussali-Galante P, Fortoul TI. 2004. Nigrostriatal modifications after vanadium inhalation and immunocytochemical and etiological approach. Neurochem. Res. 29: 1357-1362.
4. Baker AH, Edwards DR, Murphy G. 2002. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115: 3719-3727.
5. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
6. Calderon-Garcidueñas L, Azzarelli B, Acuna H, García R, Gambling TM, Osnaya N, Monroy S, Del Tizapantzi MR, Carson JL. Villareal-Calderon A, Rewcastle B. 2002. Air pollution and brain damage. Toxicol. Pathol. 30: 373-389.
7. Cross AK, Woodroofe MN. 1999. Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. Glia 28: 183-189.
8. Fortoul TI, Quan-Torres A, Sánchez I, López I, Bizarro P, Mendoza ML, Saldivar OL, Espejel-Maya G, Avila-Casado MC, Avila-Costa MR, Colín-Barenque L, Navarro VD, Olaiz-Fernandez G. 2002. Vanadium in ambient air: Concentrations in lung tissue from autopsies of Mexico City residents in the 1960s and 1990s. Arch. Environ. Health 57: 446-449.
9. Fortoul TI, Salgado RC, Moncada SG, Sánchez IG, Lopez I, Espejel G, Calderon NL, Saldívar L. 1999. Ultrastructural findings in the murine nonciliated bronchiolar cells (NCBC) after subacute inhalation of lead acetate. Acta Vet. Brno 68: 51-55.
10. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PK. 1999. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 842: 92-100.
11. García GB, Biancardi ME, Quiroga AD. 2005. Vanadium (V)-induced neurotoxicity in the rat central nervous system: a histoimmunohistochemical study. Drug Chem. Toxicol. 28: 329-344.
12. García GB, Quiroga AD, Stürtz N, Martínez AI, Biancardi ME. 2004. Morphological alterations of central nervous system (CNS) myelin in vanadium (V)-exposed adult rats. Drug Chem. Toxicol. 27: 1-13.
13. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH. 2001. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 21: 1393-1400.
14. Gijbels KP, Proost S, Masure H, Carton A, Billiau, Opdenakker G. 1993. Gelatinase B is present in the cerebrospinal fluid during EAE and cleaves myelin basic protein. J. Neurosci. Res. 36: 432-440.
15. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA. 2002. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297: 1186-1190.
16. Gutierrez-Castillo ME, Roubicek DA, Cebrian-García ME, De Vizraya-Ruiz A, Sordo-Cedeno M, Ostrosky-Wegman P. 2006. Effect of chemical composition on the induction of DNA damage by urban airborne particulate matter. Environ. Mol. Mutagen. 47: 199-211.
17. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. 1999. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J. Cereb. Blood Flow Metab. 19: 624-633.
18. Jaspers I, Samet MJ, Erzurum S, Reed W. 2000. Vanadium-induced kB-dependent transcription depends upon peroxide-induced activation of the p38 mitogen-activated protein kinase. Am. J. Respir. Cell Mol. Biol. 23: 95-102.
19. Johnston JB, Zhang K, Silva C, Shalinsky DR, Conant K, Ni W, Corbett D, Yong VW, Power C. 2001. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann. Neurol. 49: 230-241.
20. Jourquin J, Tremblay E, Decanis N, Charton G, Hanessian S, Chollet AM, Le Diguardher T, Khrestchatisky M, Rivera S. 2003. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur. J. Neurosci. 18: 1507-1517.
21. Justicia C, Panes J, Sole S, Cervera A, Deulofeu R, Chamorro A, Planas AM. 2003. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain alter occlusion/reperfusion of the middle cerebral artery in rats. J. Cereb. Blood Flow Metab. 23: 1430-1440.
22. Lee R, Kermani P, Teng KK, Hempstead BL. 2001. Regulation of cell survival by secreted proneurotrophins. Science 294: 1945-1948.
23. Liu WL, Furuichi T, Miyake M, Rosenberg GA, Liu KJ. 2007. Differential expression of tissue inhibitor of metalloproteinases-3 in cultured astrocytes and neurons regulates the activation of matrix metalloproteinase-2. J. Neurosci. Res. 85: 829-836.
24. McCawley LJ, Matrisian LM. 2001. Tumor progression: defining the soil round the tumor seed. Curr. Biol. 11: R25-R27.
25. Matyszak MK, Perry VH. 1996. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J. Neuroimmunol. 69: 141-149.
26. Mukherjee B, Patra B, Mahapatra S, Banerjee P, Tiwari A, Chatterjee M. 2004. Vanadium - an element of atypical biological significance. Toxicol. Lett. 150: 135-143.
27. Nagase H, Visse R, Murphy G. 2006. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69: 562-573.
28. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, Razhagi A, Miller K, Gearing A. 2001. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. 893: 104-112.
29. Rosenberg GA, Mun-Bryce S. 2004. Matrix metalloproteinases in neuroinflammation and cerebral ischemia. Ernst Schering Res. Found. Workshop 47: 1-16.
30. Sternlicht MD, Werb Z. 2001. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17: 463-516.
31. Suryadevara R, Holter S, Borgmann K, Persidsky R, Labenz-Zink C, Persidsky Y, Gendelman HE, Wu L, Ghorpade A. 2003. Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia 44: 47-56.
32. Szklarczyk A, Lapinska J, Rylski M, McKay RDG, Kaczmarek L. 2002. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J. Neurosci. 22: 920-930.
33. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazor M. 2006. Free radicals, metals and antioxidants in oxidative stress induced cancer. Chem. Biol. Interact. 160: 1-40.
34. Vecil GG, Larsen HP, Corley MS, Herx ML, Besson A, Goodyer GC, Yong WV. 2000. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J. Neurosci. Res. 61: 212-224.
35. Wenning R, Kirsch N. 1988. Vanadium. In Handbook on Toxicity of Inorganic Compounds. Marcel Dekker: New York; 749-765.
36. Wetzel M, Rosenberg GA, Cunningham LA. 2003. Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis. Eur. J. Neurosci. 18: 1050-1060.
37. Wu YCH, Hsieh LH, Jou JM, Yang MCh. 2004. Involvement of p42/p44 MAPK,p38 MAPK, JNK and nuclear factor-kappa B in interleukin-1beta-induced matrix metalloproteinase-9 expression in rat brain astrocytes. J. Neurochem. 90: 1477-1488.
38. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. 1998. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21: 75-80.
39. Zhang Z, Huang Ch, Li J, Leonard SS, Lanciotti R, Butterworth L, Shi X. 2001. Vanadate-induced cell growth regulation and the role of reactive oxygen species. Arch. Biochem. Biophys. 92: 311-320.